Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Florida
Cogent Biosciences, Inc.
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
City of Hope Medical Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Kyowa Kirin Co., Ltd.
MitoImmune Therapeutics
University College, London
SCRI Development Innovations, LLC
University of Liege
Baptist Health South Florida
Duke University
Northside Hospital, Inc.
National Cancer Institute (NCI)
Kiadis Pharma
Kiadis Pharma
Novartis
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center